The polio vaccine took eight years to develop and

test.

 

The MMR vaccine took eight years.

 

The HPV vaccine took fifteen years.

 

The COVID vaccines took ten months.

​

Those numbers alone should give anyone pause, but they only tell part of the story. Behind those years of development

lies a system built on caution, learned through tragedy, and designed around a simple principle: first, not

harm.

​

When Jonas Salk announced his polio vaccine in 1955, he had spent eight years methodically proving its safety and

effectiveness. Even then, the Cutter Incident - where contaminated vaccine gave children polio - reminded the world

why rushing matters of life and death is a dangerous game.

 

That disaster led to the modern regulatory framework we've relied on for nearly seventy years. Until 2020.

 

But before we can understand what changed, we need to understand what was supposed to happen. The vaccine

approval process wasn't designed by bureaucrats looking to slow down medical progress. It was built by scientists who 

had watched well-intentioned treatments kill the very people they were meant to save.

 

The Standard Playbook: Why Every Phase Matters

 

Vaccine development traditionally follows a pattern as predictable as it is thorough. First comes the preclinical

phase - two to four years of laboratory work that most people are unaware of. Scientists test their candidates on cell cultures, then on mice, then on primates, looking for the most basic question of all: Does this thing kill you

before it helps you?

 

Consider the HPV vaccine, Gardasil. Merck spent six years in preclinical development alone, testing various formulations, adjuvants, and delivery methods. They had to prove the vaccine could provoke an immune response without triggering autoimmune reactions. They had to demonstrate it wouldn't interfere with normal cellular development. They had to demonstrate that it was stable enough to withstand manufacturing and distribution.

 

Only after six years of animal testing did they feel confident enough to inject it into the first human volunteer. Phase I trials are small by design - typically just twenty to one hundred healthy volunteers, usually young adults with robust immune systems. The goal isn't to prove the vaccine works; it's to prove it won't cause immediate harm. Researchers carefully escalate the dose, watching for fever, swelling, allergic reactions, or any sign that the human immune system responds differently than laboratory animals suggest.

 

Even this cautious phase can spring surprises. During Phase I trials of an early RSV vaccine in the 1960s, children initially appeared fine. The problems only emerged later, when vaccinated children encountered wild RSV and developed enhanced disease, worse symptoms than if they'd never been vaccinated at all. Eighty children were hospitalised.

 

Two died. That vaccine never made it to Phase II.

 

Phase II: When Hope Meets Reality

 

Phase II trials expand the pool to 100 to 300 participants, but more importantly, they broaden the questions being asked. This is where researchers stop asking, "Will this kill you?" and start asking, "Will this work?" The participant pool changes, too. Instead of healthy twenty-somethings, Phase II includes populations that will need the vaccine: the elderly, the immunocompromised, children, and pregnant women - populations whose immune systems may respond differently to the same formulation that was successful in Phase I.

 

The pneumococcal vaccine provides a sobering example of why this phase matters. Early versions looked promising in healthy adults but failed spectacularly in elderly patients, the very group most at risk from pneumococcal infections. Their aged immune systems couldn't mount the robust response that younger participants had demonstrated. Back to the drawing board - three more years of reformulation and testing.

 

Phase II is also where researchers test different dosing schedules. One shot or two? Three weeks apart or six months?These aren't academic questions. The original hepatitis B vaccine required three shots over six months, but early trials tested everything from single doses to five-shot regimens. Getting the timing wrong could mean the difference between lifelong immunity and protection that fades within months. This phase typically takes two to three years, not

because researchers are moving slowly, but because  immune responses require time to develop and be measured. You can't rush antibody production, and you certainly can't accelerate the timeline for observing whether those antibodies protect against disease.

 

Phase III: The Moment of Truth

 

By the time a vaccine reaches Phase III, millions of pounds and nearly a decade of work hang in the balance. This is the phase that separates promising candidates from proven medicines - and it's where most vaccines fail. Phase III trials are massive by necessity. We're talking about one thousand to thirty thousand participants, sometimes more. The rotavirus vaccine trials involved 71,000 children across multiple countries. The original polio vaccine trials included 1.8 million children - one of the most extensive medical experiments in history.

​

These numbers aren't arbitrary. They reflect statistical reality: if a vaccine causes severe side effects in one person per ten thousand, you need to test at least fifty thousand people to have a reasonable chance of detecting the problem. Smaller trials might miss rare but serious complications entirely.

​

The RotaShield vaccine learned this lesson the hard way. Through Phase II, it was a triumph, offering adequate protection against rotavirus with minimal side effects. Even early Phase III data looked promising. But as the trials expanded, a pattern emerged: intussusception, a potentially fatal bowel obstruction, occurring in about one in ten thousand vaccinated infants.

 

One in ten thousand. A side effect so rare that smaller trials had missed it entirely, but severe enough to kill children. 

 

RotaShield was withdrawn from the market in 1998, just over a year after its approval.

 

Phase III is also where researchers encounter the messy reality of human behaviour. In controlled settings, participants follow instructions, return for scheduled visits, and accurately report their symptoms. In the real world, people often forget doses, mix medications, and lead complicated lives that can interfere with their immune responses.

 

The Lyme disease vaccine, LYMErix, appeared promising in controlled trials but began to show problems when deployed to the general population. Some patients developed autoimmune arthritis symptoms that researchers suspected were linked to the vaccine. The manufacturer voluntarily withdrew it in 2002, despite years of successful trials.

 

This is why Phase III trials typically run for one to four years. Researchers need time to observe not only immediate reactions but also delayed responses, interactions with other medications, and effectiveness across different populations and seasons.

 

The Regulatory Gauntlet: Where Independence Matters

 

After surviving Phase III trials, a vaccine candidate faces what many consider the most rigorous part of the entire process: regulatory review. This isn't a rubber stamp exercise. It's where independent experts, with no financial stake in the outcome, dissect every piece of data collected over the previous decade.

 

The FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) exemplifies how this process is supposed to work. Composed of external experts - virologists, immunologists, biostatisticians, paediatricians - this committee receives the complete trial data months before their public meeting. Every adverse event, every

statistical analysis, every manufacturing detail gets scrutinised by people whose careers depend on scientific integrity,

not pharmaceutical profits.

 

The meetings themselves are public. Manufacturers must present their data, answer pointed questions, and defend their conclusions before an audience that includes patient advocates, independent researchers, and journalists. Committee members vote on specific questions: Is the vaccine safe? Is it effective? Do the benefits outweigh the

risks for the intended population? These aren't perfunctory proceedings. In 2009, VRBPAC rejected an initial application for a seasonal flu vaccine due to insufficient safety data. The manufacturer had to conduct additional studies and return months later.

 

In 2013, they demanded additional safety monitoring for a pneumococcal vaccine before approving it. The committee has consistently demonstrated its willingness to say no, even to vaccines from major manufacturers.

 

The European Medicines Agency operates a similar system through its Committee for Medicinal Products for Human Use (CHMP). Their review process often takes longer than the FDA's, sometimes requiring additional studies or manufacturing inspections that delay approval by months or years. But the real strength of the system lies in its redundancy. Multiple regulatory agencies review the same data independently. A vaccine approved in the United States still faces

separate scrutiny in Europe, Canada, Australia, and Japan. Different agencies sometimes reach different conclusions - the rotavirus vaccine RotaTeq was approved in the US in 2006 but didn't receive European approval until 2008, after additional safety studies were conducted.

 

Manufacturing: The Hidden Complexity

 

Regulatory approval isn't just about clinical data. Before a single dose reaches the public, inspectors descend on

manufacturing facilities to verify that the company can produce the vaccine safely and consistently. Vaccine manufacturing is extraordinarily complex.

 

Unlike chemical drugs, which can be synthesised from predictable ingredients, vaccines often involve live biological

systems - cell cultures, eggs, bacteria - that can vary from batch to batch. Each step must be controlled, monitored,

and documented. The inspection process can take months. Regulators examine everything from the source of raw materials to the qualifications of laboratory technicians. They review cleaning procedures, contamination controls, and quality testing protocols. They verify that the company has systems in place to track every vial from production to the patient. Manufacturing problems have derailed vaccine approvals even after successful clinical trials. In 2009, a

contamination issue at a Merck facility delayed approval of their rotavirus vaccine by eighteen months. The company had to demonstrate that it could consistently produce a sterile vaccine before regulators would approve.

 

Post-Market Surveillance: The Safety Net That Never Sleeps

 

Even after approval, the monitoring continues. Postmarket surveillance systems, such as VAERS in the United States and the Yellow Card Scheme in the UK, collect reports of adverse events from healthcare providers and patients. These systems can detect safety signals that even significant Phase III trials may have missed. 

 

The 1976 swine flu vaccine provides the classic example. Phase III trials involving thousands of participants detected no unusual safety signals. But within months of the mass vaccination campaign, epidemiologists noticed an uptick in cases of Guillain-Barr. syndrome, a rare autoimmune condition affecting the nervous system. The association was weak - about one extra case per 100,000 vaccinations - but the surveillance system caught it. The vaccination programme was halted, investigations were launched, and the vaccine was withdrawn. The entire episode reinforced why ongoing monitoring matters: some risks only become apparent when millions of people receive a vaccine.

 

This is why vaccine safety monitoring is an ongoing process. Even vaccines that have been in use for decades continue to be tracked through multiple surveillance systems. The MMR vaccine, approved in 1971, continues to be monitored through ongoing studies involving millions of children.

​

Why the System Worked

 

For nearly seventy years, this methodical approach protected public health whilst advancing medical science. Yes, it was slow. Yes, it was expensive. But it was also remarkably effective at preventing the deployment of dangerous or ineffective vaccines. The system's strength lay in its conservative bias. It is better to delay a useful vaccine than to deploy a harmful

one. It is better to demand additional data than to assume safety. It is better to err on the side of caution when administering

interventions to healthy individuals, including children.

 

This philosophy shaped every aspect of vaccine development, from the design of clinical trials to the structure of regulatory agencies. It created a culture where asking "what could go wrong?" wasn't pessimism - it was professional responsibility.

That culture, and the system it built, had guided vaccine development through the conquest of polio, the elimination of smallpox, and the prevention of countless childhood diseases.

​

Then came 2020, and everything changed.

​

​

This is an excerpt from The Pandemic Profiteers